Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CLDN's Cash to Debt is ranked higher than
72% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CLDN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CLDN' s Cash to Debt Range Over the Past 10 Years
Min: 5.48  Med: 9999.00 Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -1.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -87.52
CLDN's ROE (%) is ranked lower than
78% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CLDN: -87.52 )
Ranked among companies with meaningful ROE (%) only.
CLDN' s ROE (%) Range Over the Past 10 Years
Min: -320.68  Med: -320.68 Max: -320.68
Current: -87.52
ROA (%) -71.35
CLDN's ROA (%) is ranked lower than
80% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CLDN: -71.35 )
Ranked among companies with meaningful ROA (%) only.
CLDN' s ROA (%) Range Over the Past 10 Years
Min: -87.49  Med: -70.06 Max: -61.4
Current: -71.35
-87.49
-61.4
ROC (Joel Greenblatt) (%) -8266.86
CLDN's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CLDN: -8266.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -25840.98  Med: -9317.21 Max: -6183.38
Current: -8266.86
-25840.98
-6183.38
» CLDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CLDN Guru Trades in

Q4 2014

CLDN Guru Trades in Q4 2014

Steven Cohen 7,400 sh (New)
Jim Simons 21,600 sh (New)
» More
Q1 2015

CLDN Guru Trades in Q1 2015

George Soros 120,000 sh (New)
Jim Simons 298,300 sh (+1281.02%)
Steven Cohen Sold Out
» More
Q2 2015

CLDN Guru Trades in Q2 2015

Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CLDN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.55
CLDN's P/B is ranked higher than
96% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CLDN: 0.55 )
Ranked among companies with meaningful P/B only.
CLDN' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 6.5
Current: 0.55
0
6.5
EV-to-EBIT 0.38
CLDN's EV-to-EBIT is ranked higher than
97% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. CLDN: 0.38 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDN' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.38
Current: 0.38
0
0.38
EV-to-EBITDA 0.38
CLDN's EV-to-EBITDA is ranked higher than
97% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. CLDN: 0.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLDN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.38
Current: 0.38
0
0.38
Current Ratio 21.20
CLDN's Current Ratio is ranked higher than
90% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CLDN: 21.20 )
Ranked among companies with meaningful Current Ratio only.
CLDN' s Current Ratio Range Over the Past 10 Years
Min: 2.83  Med: 13.33 Max: 21.2
Current: 21.2
2.83
21.2
Quick Ratio 21.20
CLDN's Quick Ratio is ranked higher than
91% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CLDN: 21.20 )
Ranked among companies with meaningful Quick Ratio only.
CLDN' s Quick Ratio Range Over the Past 10 Years
Min: 2.83  Med: 13.33 Max: 21.2
Current: 21.2
2.83
21.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.61
CLDN's Price/Net Cash is ranked higher than
97% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. CLDN: 0.61 )
Ranked among companies with meaningful Price/Net Cash only.
CLDN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.71  Med: 4.11 Max: 8.13
Current: 0.61
0.71
8.13
Price/Net Current Asset Value 0.59
CLDN's Price/Net Current Asset Value is ranked higher than
97% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. CLDN: 0.59 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.69  Med: 4.07 Max: 7.89
Current: 0.59
0.69
7.89
Price/Tangible Book 0.59
CLDN's Price/Tangible Book is ranked higher than
97% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. CLDN: 0.59 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.69  Med: 4.04 Max: 7.76
Current: 0.59
0.69
7.76
Earnings Yield (Greenblatt) (%) 305.02
CLDN's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CLDN: 305.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -37430.55  Med: 0.00 Max: 90336.48
Current: 305.02
-37430.55
90336.48

More Statistics

EPS $ -2.17
Short Percentage of Float3.13%
52-Week Range $0.86 - 28.25
Shares Outstanding(Mil)23.92

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil)
EPS($) -1.48 -0.94 -1.58
EPS without NRI($) -1.48 -0.94 -1.58

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:72C.Germany,
Celladon Corp was incorporated in California on December 21, 2000 and reincorporated in Delaware in April 2012. The Company is a clinical-stage biotechnology with industry expertise in the development of cardiovascular gene therapy. Its programs target sarco/endoplasmic reticulum Ca2+ -ATPase, or SERCA, enzymes, which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function resulting in inadequate blood flow to meet the body's metabolic needs, as well as blood vessel health, diabetes and neurodegenerative diseases. SERCA2a, an enzyme that becomes deficient in patients with heart failure, was scientifically validated as a molecular target for heart failure in the 1990s and became a focus of internal discovery efforts for many large pharmaceutical companies. Its therapeutic portfolio includes both gene therapies and small molecule compounds targeting diseases characterized by SERCA enzyme deficiency. MYDICAR, its advanced product candidate, uses gene therapy to target SERCA2a. Its suppliers include Lonza and Novasep, for the manufacturing of its viral vectors and product candidates for clinical testing purposes. The Company expect to rely upon Lonza, Novasep, and/or other third parties to produce materials required for the commercial production of its product candidates and companion diagnostic. Its commercial strategy involving a progressive build out of commercial infrastructure in the United States covering key prescribers and centers of excellence is one that they can realistically pursue. The Company face potential competition from many different sources, including larger and funded pharmaceutical companies. Its competitors include Renova Therapeutics, NanoCor Therapeutics, Juventas Therapeutics, VentriNova and Beat BioTherapeutics. Biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. The Company requires to obtain FDA approval before clinical testing of a biological product begins, and each clinical trial protocol for a gene therapy product is reviewed by the FDA and, in some instances, the U.S. National Institutes of Health, or NIH, through its Recombinant DNA Advisory Committee, or RAC.
» More Articles for CLDN

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 

More From Other Websites
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 10 2016
Celladon Sets Date for Special Meeting of Stockholders Feb 10 2016
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 19 2016
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2016
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 16 2015
CELLADON CORP Financials Dec 08 2015
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 01 2015
CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 23 2015
6 BioHealth Movers That Now Cannot Be Ignored Nov 21 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement... Nov 19 2015
Celladon (CLDN) Stock Popping on Eiger Merger Nov 19 2015
CELLADON ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation into the... Nov 19 2015
CELLADON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with... Nov 19 2015
CELLADON CORP Files SEC form 10-Q, Quarterly Report Nov 09 2015
CELLADON CORP Files SEC form 8-K, Change in Directors or Principal Officers Sep 30 2015
CELLADON CORP Files SEC form 8-K, Termination of a Material Definitive Agreement Sep 15 2015
Spark Tries to Quell Investor Fears About Gene Therapy Test Sep 10 2015
72-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of August 31, 2015 Lead... Aug 28 2015
Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on Behalf of Celladon... Aug 26 2015
GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors Aug 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK